Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSEN1 | P49768 | 8/20 | 0.37 |
| ▸ | PSEN2 | P49810 | 8/20 | 0.37 |
| ▸ | APH1B | Q8WW43 | 8/20 | 0.37 |
| ▸ | NCSTN | Q92542 | 8/20 | 0.37 |
| ▸ | APH1A | Q96BI3 | 8/20 | 0.37 |
| ▸ | PSENEN | Q9NZ42 | 8/20 | 0.37 |
| ▸ | SPPL2A | Q8TCT8 | 1/20 | 0.36 |
| ▸ | EIF2S1 | P05198 | 5/20 | 0.33 |
| ▸ | EIF2AK3 | Q9NZJ5 | 5/20 | 0.33 |
| ▸ | TRPV1 | Q8NER1 | 3/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.33 |
| ▸ | MMP1 | P03956 | 1/20 | 0.33 |
| ▸ | MMP2 | P08253 | 1/20 | 0.33 |
| ▸ | MMP9 | P14780 | 1/20 | 0.33 |
| ▸ | MMP8 | P22894 | 1/20 | 0.33 |
| ▸ | PDE2A | O00408 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2958931 | 1.00 | PSEN1 (0.37) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL13265511 | 0.94 | PSEN1 (0.38) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL8321409 | 0.94 | PSEN1 (0.38) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL2958782 | 0.94 | PSEN1 (0.38) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL8314712 | 0.94 | TRPV1 (0.35) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL2961189 | 0.94 | TRPV1 (0.35) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL8316873 | 0.93 | PSEN1 (0.37) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL2962942 | 0.93 | PSEN1 (0.37) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL8313682 | 0.92 | PSEN1 (0.38) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL2958410 | 0.92 | PSEN1 (0.38) | PSEN1PSEN2APH1BNCSTNAPH1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1633350-B1 | ACYLATED AMINO ACID AMIDYL PYRAZOLES AND RELATED COMPOUNDS | ELAN PHARM INC (US) | 2012-10-03 | — | — | EP | disclosed |
| US-20100280066-A1 | ACYLATED AMINO ACID AMIDYL PYRAZOLES AND RELATED COMPOUNDS | TUNG JAY S | 2010-11-04 | — | — | US | disclosed |
| US-20100280066-A1 | ACYLATED AMINO ACID AMIDYL PYRAZOLES AND RELATED COMPOUNDS | TUNG JAY S | 2010-11-04 | — | — | US | disclosed |
| US-7759382-B2 | such as N-{5-[1-(4-chloro-phenyl)-1-methyl-ethyl]-2H-pyrazol-3-yl}-2-[2-(3,5-difluoro-phenyl)-2-hydroxy-acetylamino]-propionamide, used for inhibiting beta-amyloid peptide release and/or biosynthesis, inhibiting gamma-secretase activity, prevention and treatment of Alzheimer's disease | ELAN PHARMACEUTICALS, INC. (US) | 2010-07-20 | — | — | US | disclosed |
| US-7759382-B2 | such as N-{5-[1-(4-chloro-phenyl)-1-methyl-ethyl]-2H-pyrazol-3-yl}-2-[2-(3,5-difluoro-phenyl)-2-hydroxy-acetylamino]-propionamide, used for inhibiting beta-amyloid peptide release and/or biosynthesis, inhibiting gamma-secretase activity, prevention and treatment of Alzheimer's disease | ELAN PHARMACEUTICALS, INC. (US) | 2010-07-20 | — | — | US | disclosed |
| US-20070197624-A1 | Acylated amino acid amidyl pyrazoles and related compounds | ELAN PHARMACEUTICALS, INC. (US) | 2007-08-23 | — | — | US | disclosed |
| US-20070197624-A1 | Acylated amino acid amidyl pyrazoles and related compounds | ELAN PHARMACEUTICALS, INC. (US) | 2007-08-23 | — | — | US | disclosed |
| WO-2005009344-A2 | ACYLATED AMINO ACID AMIDYL PYRAZOLES AND RELATED COMPOUNDS | ELAN PHARMACEUTICALS, INC. (US) | 2005-02-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100280066-A1 | ACYLATED AMINO ACID AMIDYL PYRAZOLES AND RELATED COMPOUNDS | APP, BACE1, APH1A | PSEN1 7/4885PSEN2 13/4885APH1B 4/4885 |
| US-20070197624-A1 | Acylated amino acid amidyl pyrazoles and related compounds | APP, BACE1, APH1A | PSEN1 7/4885PSEN2 13/4885APH1B 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.